middle.news
Why Did Racura Oncology Swing to a $4.1M Loss Despite Clinical Breakthroughs?
12:52pm on Friday 27th of February, 2026 AEDT
•
Healthcare
Read Story
Why Did Racura Oncology Swing to a $4.1M Loss Despite Clinical Breakthroughs?
12:52pm on Friday 27th of February, 2026 AEDT
Key Points
H1 FY26 loss of $4.1 million versus prior profit
New patent applications filed for bisantrene drug
Progress in clinical trials for RC220 in AML and NSCLC
Cash reserves increased to $20.9 million via option exercises and private placement
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RACURA ONCOLOGY (ASX:RAC)
OPEN ARTICLE